Candida glabrata Endophthalmitis Treated Successfully with Caspofungin

Sarria, Juan C.; Bradley, Jay; Habash, Ranya; Mitchell, Kelly; Kimbrough, Robert C.; Vidal, Ana Maria Centola

doi:10.1086/427753

Cited by 63 publications

(30 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the first of the echinocandins to be approved for the treatment of IC, caspofungin has been used extensively for the treatment of all forms of serious candidal infections over the past 4 years (87,114,134,171,261). Thus far, clinical experience with caspofungin and IC has been good (41,87,114,163,171).…”

Section: Trends In Antifungal Susceptibility In Relation To Time Geomentioning

confidence: 99%

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

2007

View full text Add to dashboard Cite

SUMMARY Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United States. We examined data from the National Center for Health Statistics and reviewed recent literature in order to update the epidemiology of IC. IC-associated mortality has remained stable, at approximately 0.4 deaths per 100,000 population, since 1997, while mortality associated with invasive aspergillosis has continued to decline. Candida albicans remains the predominant cause of IC, accounting for over half of all cases, but Candida glabrata has emerged as the second most common cause of IC in the United States, and several less common Candida species may be emerging, some of which can exhibit resistance to triazoles and/or amphotericin B. Crude and attributable rates of mortality due to IC remain unacceptably high and unchanged for the past 2 decades. Nonpharmacologic preventive strategies should be emphasized, including hand hygiene; appropriate use, placement, and care of central venous catheters; and prudent use of antimicrobial therapy. Given that delays in appropriate antifungal therapy are associated with increased mortality, improved use of early empirical, preemptive, and prophylactic therapies should also help reduce IC-associated mortality. Several studies have now identified important variables that can be used to predict risk of IC and to help guide preventive strategies such as antifungal prophylaxis and early empirical therapy. However, improved non-culture-based diagnostics are needed to expand the potential for preemptive (or early directed) therapy. Further research to improve diagnostic, preventive, and therapeutic strategies is necessary to reduce the considerable morbidity and mortality associated with IC.

show abstract

Section: Trends In Antifungal Susceptibility In Relation To Time Geomentioning

confidence: 99%

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

2007

View full text Add to dashboard Cite

show abstract

“…The potent, broad-spectrum fungicidal activity of caspofungin against Candida spp. has led to extensive use of this agent for the treatment of all forms of serious candidal infections over the past 4 years (9,12,17,25). Thus far, clinical experience with caspofungin and invasive candidiasis has been good (9,14,17).…”

mentioning

confidence: 99%

In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

Pfaller¹,

Boyken²,

Hollis³

et al. 2006

J Clin Microbiol

176

130

View full text Add to dashboard Cite

Of the 25 isolates with caspofungin MICs of >1 g/ml, 12 isolates were C. parapsilosis, 6 isolates were C. guilliermondii, 2 isolates were C. rugosa, and 1 isolate each was C. albicans, C. glabrata, C. krusei, C. lusitaniae, and C. tropicalis. There was no significant change in caspofungin activity over the 4-year study period. Likewise, there was no difference in activity by geographic region. Caspofungin has excellent in vitro activity against invasive clinical isolates of Candida from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates of Candida.

show abstract

“…The case of a 39-year-old patient with endophthalmitis resulting from complicated abdominal surgery has been published, successfully treated with intravenous caspofungin. 5 A case of endophthalmitis subsequent to urologic surgery has also been published, successfully treated with amphotericin B and flucytosine lipid complex. 7 Treatment regimens for endophthalmitis with fungal etiology include various combinations of systemic or intravitreal antifungals plus vitrectomy.…”

Section: Discussionmentioning

confidence: 99%

“…3 Although endogenous fungal endophthalmitis has been reported, bilateral ocular involvement is a less common condition. 4 Even less is endogenous endophthalmitis from Candida glabrata [5][6][7] (C. glabrata). There are no papers reporting bilateral endogenous endophthalmitis from C. glabrata.…”

Section: Introductionmentioning

confidence: 99%